Description
Product Overview
Rafinlar® Capsules contain Dabrafenib, a targeted cancer therapy developed to help treat specific cancers associated with the BRAF V600 gene mutation. Manufactured by Novartis India Ltd, Rafinlar belongs to a class of medicines known as BRAF inhibitors, designed to slow or stop the growth of cancer cells by targeting abnormal proteins responsible for tumor development.
Rafinlar is widely used in oncology treatment protocols for patients diagnosed with unresectable or metastatic melanoma, as well as certain cases of non-small cell lung cancer (NSCLC) and anaplastic thyroid cancer carrying the BRAF V600 mutation. It is commonly prescribed alone or in combination with Trametinib to improve treatment outcomes and delay resistance.
Product Details
- Brand Name: Rafinlar®
- Generic Name: Dabrafenib
- Dosage Form: Capsules
- Therapeutic Class: Targeted Cancer Therapy / BRAF Inhibitor
- Manufacturer: Novartis India Ltd
- Supply Type: Manufacturer, Exporter, Supplier, Distributor, Trader
- Minimum Order Quantity (MOQ): 20 Bottles
- Preferred Buyer Location: Worldwide
What Is Rafinlar Used For?
Rafinlar (Dabrafenib) is prescribed for the treatment of cancers with a confirmed BRAF V600 mutation, including:
✔ Metastatic or Unresectable Melanoma
Used in adults with melanoma that cannot be surgically removed or has spread to other parts of the body.
✔ Adjuvant Melanoma Therapy
Used after surgery in combination with Trametinib to reduce the risk of melanoma returning.
✔ Non-Small Cell Lung Cancer (NSCLC)
For advanced NSCLC patients with BRAF V600E mutation-positive tumors.
✔ Anaplastic Thyroid Cancer
Used in combination therapy for BRAF V600E mutation-positive thyroid cancer.
Mechanism of Action
Rafinlar works by targeting and blocking the activity of the mutated BRAF protein, which is responsible for sending abnormal signals that encourage uncontrolled cancer cell growth. By inhibiting this pathway, Dabrafenib helps slow tumor progression and may contribute to tumor shrinkage in eligible patients.
Dosage & Administration
- Administered orally in capsule form
- Should be taken on an empty stomach:
- At least 1 hour before meals
- Or 2 hours after meals
- Dosage and treatment duration must be determined by a qualified oncologist based on the patient’s condition and treatment plan.
Possible Side Effects
Patients using Rafinlar may experience certain side effects, including:
Common Side Effects:
- Fever and chills
- Fatigue
- Headache
- Nausea or vomiting
- Diarrhea
- Skin rash
- Joint pain
- Hair thinning or hair loss
- Cough and abdominal discomfort
Serious Side Effects:
- Heart-related complications
- Liver problems
- Eye inflammation (uveitis)
- Bleeding disorders
- Development of secondary skin cancers
Regular monitoring and medical supervision are recommended throughout treatment.
Important Safety Information
- Genetic testing is required before treatment to confirm the presence of the BRAF V600 mutation
- Not recommended during pregnancy
- Effective contraception is advised during treatment
- Patients should undergo regular skin examinations and routine medical assessments during therapy
Why Choose Rafinlar®?
✔ Trusted targeted oncology treatment
✔ Manufactured by Novartis India Ltd
✔ Globally recognized cancer therapy
✔ Designed specifically for BRAF mutation-positive cancers
✔ Worldwide supply and export available
✔ Professional pharmaceutical distribution support
Worldwide Supply & Distribution
We supply authentic Rafinlar® (Dabrafenib) Capsules for hospitals, oncology centers, pharmacies, distributors, healthcare providers, and approved buyers worldwide. Bulk orders and international shipping options are available based on buyer requirements.
Medical Disclaimer
This product should only be used under the supervision of a qualified healthcare professional. The information provided is for educational and informational purposes only and does not replace medical advice, diagnosis, or treatment.
Reviews
There are no reviews yet.